SCHEMBL35210436

SCHEMBL35210436

O=Cc1ccc(-c2noc(-c3ccc(O)cc3)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH5A1 P51649 1/20 0.52
ABAT P80404 1/20 0.52
NPC1 O15118 8/20 0.50
MAPT P10636 5/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
NFKB1 P19838 3/20 0.50
NFKB2 Q00653 3/20 0.50
RELA Q04206 3/20 0.50
NPSR1 Q6W5P4 3/20 0.50
HSD17B10 Q99714 2/20 0.50
PKM P14618 1/20 0.50
NR1H4 Q96RI1 4/20 0.49
RAB9A P51151 7/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
CA2 P00918 4/20 0.43
CA9 Q16790 4/20 0.43
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
S1PR1 P21453 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3456771 0.84 NPC1 (0.66) NPC1MAPTSMN1; SMN2NFKB1NFKB2
SCHEMBL13284680 0.81 RAB9A (0.47) ALDH5A1ABATNPC1MAPTSMN1; SMN2
SCHEMBL19287102 0.80 TYR (0.56) NPC1MAPTSMN1; SMN2NFKB1NFKB2
SCHEMBL4744783 0.80 LMNA (0.65) NPC1MAPTNPSR1RAB9AS1PR1
SCHEMBL4741824 0.80 NPC1 (0.67) NPC1MAPTSMN1; SMN2NFKB1NFKB2
SCHEMBL27767785 0.80 NPC1 (0.48) NPC1MAPTSMN1; SMN2NFKB1NFKB2
SCHEMBL3061782 0.80 NR1H4 (0.78) NPC1MAPTSMN1; SMN2NFKB1NFKB2
SCHEMBL15706789 0.80 NR1H4 (0.71) NPC1MAPTSMN1; SMN2NFKB1NFKB2
SCHEMBL2062609 0.80 NR1H4 (0.78) NPC1MAPTSMN1; SMN2NFKB1NFKB2
SCHEMBL12270961 0.79 NPC1 (0.54) NPC1MAPTSMN1; SMN2NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125371-A1 METHOD FOR INHIBITING CLOSTRIDIOIDES DIFFICILE SPORE GERMINATION UNIVERSITY OF NOTRE DAME DU LAC (US) 2026-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125371-A1 METHOD FOR INHIBITING CLOSTRIDIOIDES DIFFICILE SPORE GERMINATION CYP8B1, SPOUT1, O60361 ALDH5A1 1374/4885ABAT 733/4885NPC1 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.